Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2639 • ACR Convergence 2025
Gut Microbiome Signatures Forecast Clinical Response to Methotrexate in Treatment-Naïve Early Rheumatoid Arthritis
VINOD GUPTA¹, Adam Koller¹, Benjamin Hur¹, Marissa Bailey¹, Kara Delger², Elena myasoedova¹, Vanessa Kronzer¹, John Davis¹ and Jaeyun Sung¹, ¹Mayo Clinic, ROCHESTER, MN, ²Mayo Clinic, St Charles, MN
Background/Purpose: Oral methotrexate (MTX) is the cornerstone treatment for newly diagnosed rheumatoid arthritis (RA), yet up to 50% of patients do not respond adequately. Early…
Abstract Number: 2288 • ACR Convergence 2025
Efficacy of Ivarmacitinib in Patients with Moderate-to-severe Rheumatoid Arthritis Stratified by Baseline Characteristics: A Post-hoc Study of a Phase III Clinical Trial
Yuan Xue, Bo Wei, Xiaojing Huang and Rui Ding, Zhongshan Hospital Xiamen University, Xiamen, China (People's Republic)
Background/Purpose: Ivarmacitinib (SHR0302), a selective Janus kinase 1 inhibitor, has demonstrated efficacy in patients with moderate-to-severe rheumatoid arthritis (RA). This post-hoc study aimed to evaluate…
Abstract Number: 2272 • ACR Convergence 2025
Combination Therapy with TNF Inhibitors and JAK Inhibitors in Multi-Drug-Resistant Rheumatoid Arthritis: A Case Series from the RA UCLouvain Brussels Cohort
Francesco NATALUCCI¹, Cécile VAN MULLEM¹, Aleksandra AVRAMOVSKA¹, Tatiana SOKOLOVA² and Patrick Durez¹, ¹Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, ²Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Brussels Hoofdstedelijk Gewest, Belgium
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease with persistent synovial inflammation. Several bDMARDs and tsDMARDs target different key players in the immune-regulatory pathways,…
Abstract Number: 2256 • ACR Convergence 2025
Improved Outcomes of Acute Myocardial Infarction Among Patients with Rheumatoid Arthritis: A Propensity Matched National Study
Qurat Ul Ain¹ and MIrza faris Ali Baig², ¹Medstar Georgetown University Hospital, Arlington, VA, ²Medstar Health, Arlington, VA
Background/Purpose: The increased risk of cardiovascular morbidity and mortality with rheumatoid arthritis has been increasingly acknowledged over the past decades. Cardiovascular disease risk management for…
Abstract Number: 2240 • ACR Convergence 2025
Diabetes Significantly Amplifies Risk of Cardiac Arrhythmias in Rheumatoid Arthritis Patients: Results from a Multi-Center Electronic Health Record Study
Godbless Ajenaghughrure¹, Sila Mateo Faxas², Gurjot Singh³, Nirys Mateo Faxas⁴, Kim Nguyen³, Nicole Tejeda⁵ and Kimberly Ramirez Bonetti⁶, ¹Trihealth Good Samaritan Hospital, Cincinnati, OH, ²Good Samaritan Hospital, Cincinnati, OH, ³Trihealth Good Samaritan Hospital, Cincinnati, ⁴Independent Author, Santo Domingo, Dominican Republic, ⁵Independent Author, Cincinnati, ⁶Independent Author, cincinnati, OH
Background/Purpose: Both rheumatoid arthritis (RA) and type 2 diabetes mellitus (T2DM) are independently associated with increased cardiovascular risk. However, the impact of T2DM on cardiac…
Abstract Number: 2197 • ACR Convergence 2025
Mechanisms of Fetal Growth Restriction in Rheumatologic Autoimmune Diseases: Insights into Placental Pathology and Immune Dysregulation
Larabe Farrukh¹, Ananya Venkatesh², Mana Parast² and Chelsey Smith³, ¹University of California San Diego, San Diego, CA, ²University of California San Diego, San Diego, ³University of California San Diego, LA JOLLA, CA
Background/Purpose: Fetal growth restriction (FGR) significantly contributes to adverse pregnancy outcomes (APOs) in women with rheumatologic diseases. Understanding the immunopathologic mechanisms underlying FGR is critical…
Abstract Number: 1947 • ACR Convergence 2025
Coronary computed tomography incidental findings in rheumatoid arthritis.
Emmanuel Tapia López¹, Jessica Roldan Ortega², Evelyn Aranda Cano³, Itzel Palafox Sosa⁴, Luz Viruel⁵, Luis H Silveira⁶, Laura Aline Martinez-Martinez⁷ and Francisco Castillo-Castellon⁸, ¹Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Naucalpan de Juarez, Estado de México, Mexico, ²INSTITUTO NACIONAL DE CARDIOLOGIA, Ciudad de México, Federal District, Mexico, ³Departament of rheumatology Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de Mexico, Federal District, Mexico, ⁴Escuela Superior de Medicina-Instituto Politècnico Nacional, ciudad de mexico, Federal District, Mexico, ⁵Universidad Autónoma del Estado de Hidalgo, Tula de Allende, Hidalgo, Mexico, ⁶Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico, ⁷Rheumatology Department at National Institute of Cardiology Ignacio Chávez, Mexico City, Federal District, Mexico, ⁸Instituto Nacional de Cardiología Ignacio Chavez, Mexico
Background/Purpose: Patients with rheumatoid arthritis (RA) have a greater cardiovascular risk than does the general population. The coronary calcium score is a measure used to…
Abstract Number: 1880 • ACR Convergence 2025
Rheumatoid Arthritis Mortality in the U.S. (1999–2020): A Decline in Rates, But Not in Disparities
Aziz-ur-Rahman Khalid¹, Ghassan Makhoul², Hasan Munshi², Islam Rajab², Emmanuel Olumuyide³, MD Walid Akram Hussain², Aqsa Sorathia², Elvira Assaf², Amer Al Badawy², John Salama² and Robert Lahita⁴, ¹St. Joseph's University Medical Center, wayne, ²St. Josephs University Medical Center, Paterson, ³Advocate Illinois Masonic Medical Center, Chicago, ⁴St. Josephs University Medical Center, Wayne, NJ
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease associated with increased morbidity and mortality. While treatments have evolved, national trends and sociodemographic disparities in…
Abstract Number: 1695 • ACR Convergence 2025
The B Cell Compartment Exhibits a Pro-Inflammatory Skewing During Progression to Rheumatoid Arthritis
Ziyuan He¹, Marla Glass¹, Mark Gillespie¹, Elisabeth Dornisch¹, Pravina Venkatesan², Troy Torgerson³, Kevin Deane⁴, Gary Firestein⁵, Adam Savage¹, Xiaojun Li¹, V. Michael Holers⁶, Fan Zhang⁷, David Boyle⁸, Christy Bennett¹, Kristine Kuhn⁹, Kristen Demoruelle¹⁰, Peter Skene¹¹ and Ananda Goldrath¹¹, ¹Allen Institute for Immunology, Seattle, WA, ²Allen Insitute, Seattle, WA, ³Allen Institute for Immunology, Enumclaw, WA, ⁴University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁵University of California, San Diego, San Diego, CA, ⁶University of Colorado, Denver, CO, ⁷The University of Colorado, Aurora, CO, ⁸UCSD, La Jolla, CA, ⁹²⁰²² - ²⁰²³ / Adult/ University of Colorado, Aurora, CO, ¹⁰University of Colorado Anschutz Medical Campus, Golden, CO, ¹¹Allen Institute for Immunology, Seattle
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation and bone destruction. RA is preceded by a subclinical phase defined by elevated…
Abstract Number: 1644 • ACR Convergence 2025
Longitudinal Trajectory Models to Assess Pain and Risk of Difficult-to-Treat Rheumatoid Arthritis
Misti Paudel¹, Leah Santacroce², Nancy Shadick³, Michael Weinblatt⁴ and Daniel Solomon⁵, ¹Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham & Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Prior studies have observed that patient-reported outcomes, such as pain, are risk factors for progression to difficult-to-treat RA (D2T-RA), a state of multi-treatment failure.…
Abstract Number: 1360 • ACR Convergence 2025
Evaluating Causal Effects of Biologic and Targeted Synthetic Disease-modifying Anti-rheumatic Drugs Targets in Rheumatoid Arthritis Using Mendelian Randomisation
Mihye Kwon¹, Chung-il Joung¹ and Young Soo Song², ¹Konyang University Hospital, Daejeon, Republic of Korea, ²Konyang University Hospital, Daejeon, Taejon-jikhalsi, Republic of Korea
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease in which biologic and targeted synthetic DMARDs (bDMARDs, tsDMARDs) have substantially improved clinical outcomes. While randomized…
Abstract Number: 1343 • ACR Convergence 2025
Six-Minute Walk Distance as a Functional Measure in Rheumatoid Arthritis-associated Interstitial Lung Disease Reflecting Both Lung and Joint Involvement
Sung Hae Chang¹, You-Jung Ha², Sung Won Lee³, Misti Paudel⁴, Gregory McDermott⁵, Qianru Zhang⁶, Min Uk Kim⁷, Jeong Seok Lee⁸, Chan Ho Park⁹, Ji-Won Kim¹⁰, Jang Woo Ha¹¹, SANGWAN CHUNG¹², Eun Ha Kang¹³, Yeon-Ah Lee¹², Yong-Beom Park¹⁴, Jung-Yoon Choe¹⁵, Eun Young Lee¹⁶ and Jeffrey Sparks¹⁷, ¹Soonchunhyang University College of Medicine, Cheonan, MA, South Korea, ²Seoul National University Bundang Hospital, Seongnam, South Korea, ³Soon Chun Hyang University Hospital, Seoul, South Korea, ⁴Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁵Brigham and Women's Hospital, Brookline, MA, ⁶Harvard Medical School, Boston, MA, ⁷SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, ⁸Korea Advanced Institute of Science and Technology, KAIST, DaeJeon, Republic of Korea, ⁹Soonchunhyang University College of Medicine, Cheonan, Republic of Korea, ¹⁰Daegu Catholic University School of Medicine, Nam-gu, Daegu, Republic of Korea, ¹¹Division of Rheumatology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Republic of Korea, ¹²Kyung Hee University Medical Center, seoul, Republic of Korea, ¹³Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ¹⁴Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, ¹⁵Division of Rheumatology, Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Republic of Korea, ¹⁶Seoul National University College of Medicine, Seoul, South Korea, ¹⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: The six-minute walk distance (6MWD) measures functional capacity in cardiopulmonary diseases, predicts mortality in interstitial lung disease (ILD), and is used as an endpoint…
Abstract Number: 1326 • ACR Convergence 2025
Association Between Physical Function and Nutritional Status in Rheumatoid Arthritis Patients
Yasumori Sobue¹, Mochihito Suzuki², Yoshifumi Ohashi³, Shuji Asai² and Shiro Imagama², ¹Sobue Orthopedic Clinic Yatomi, Aichi, Japan, ²Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Aichi Medical University, Graduate School of Medicine, Aichi, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease that primarily affects the joints but also has substantial implications for physical function. Persistent inflammation may…
Abstract Number: 1311 • ACR Convergence 2025
Decade-Based Trends in First Remission Among Rheumatoid Arthritis Patients: A Population-Based Study
Georges El Hasbani¹, Roslin George², Anne Shurtz¹, Cynthia Crowson³ and Elena myasoedova², ¹Mayo Clinic, Rochester, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Stewartvillle, MN
Background/Purpose: Early and aggressive treatment of rheumatoid arthritis (RA) has been linked to improved remission rates, but achieving early and sustained remission remains a challenging…
Abstract Number: 1189 • ACR Convergence 2025
Clinical Outcomes and Response to SARS-Cov-2 Infection and Vaccination in Ianalumab‑Treated Patients with Autoimmune Diseases
Valerie Devauchelle¹, Swati Ghanshani², CAROLE SIPS³, Rainer Hillenbrand³, Carol Lau⁴, Wolfgang Hueber⁵, Claire Bonal³ and Stephen Oliver⁶, ¹UBO, Brest, France, ²Novartis Healthcare Private Limited, Hyderabad, India, Hyderabad, India, ³Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁴Novartis Pharmaceuticals Corporation, East Hanover, ⁵Novartis Pharmaceuticals, Basel, Switzerland, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Ianalumab, a glycoengineered IgG1 mAb directed against B cell-activating factor (BAFF)-receptor (BAFF-R), targets B cells and their functions via dual mechanism: depletion of B…

« Previous Page
1
…
7
8
9
10
11
…
219
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].